ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2015
Cannabinoids and Epilepsy.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it, 274 citations in OpenAlex.
- Efficacy and safety of medical cannabinoids in children with cerebral palsy: a systematic review.Einstein (Sao Paulo, Brazil) · 2023Pooled it
- Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood.PloS one · 2016Trial
- Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus.Brain sciences · 2026Article
- UVA and UVB Photolysis of Natural and Synthetic Cannabinoids Studied by Online Mass Spectrometry.Molecules (Basel, Switzerland) · 2026Article
- Antiseizure Effects of Cannabidiol in Combination With Cannabigerol in the Maximal Electroshock Seizure Model.Basic & clinical pharmacology & toxicology · 2026Article
- The role of cannabis in epilepsy illustrated by two case reports.Epilepsy & behavior reports · 2025Article
- Cannabizetol, a Novel Cannabinoid: Chemical Synthesis, Anti-inflammatory Activity and Extraction fromJournal of natural products · 2025Article
- Perioperative Repercussions of Cannabis Use-Implications for GI Endoscopy Sedation.Journal of clinical medicine · 2025Review
- Cannabidiol dampens propagation of hippocampal hyperactivity and differentially modulates feedforward and feedback inhibition.bioRxiv : the preprint server for biology · 2025Article
- Association Between Cannabis Use and Neuropsychiatric Disorders: A Two-sample Mendelian Randomization Study.Alpha psychiatry · 2025Article
- Recreational drugs repurposed for medicinal use-cannabis.CNS spectrums · 2025Review
- EngineeringBiotechnology reports (Amsterdam, Netherlands) · 2025Article
- Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome.Brain, behavior, & immunity - health · 2025Article
- Effects of repeated voluntary oral consumption of synthetic delta-9-tetrahydrocannabinol on locomotor activity and cannabinoid receptor 1 expression.Behavioural brain research · 2025Article
- Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review.Frontiers in pharmacology · 2025Review
- Epilepsy, neuroinflammation and cannabidiol What do we know thus far?Frontiers in pharmacology · 2025Review
- Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.Current pharmaceutical design · 2025Review
- Case Report: White-Sutton syndrome and cannabidiol, an update on a reported patient with a successful response to off--label therapy.Frontiers in pediatrics · 2025Article
- Antiseizure Medications: Advancements, Challenges, and Prospects in Drug Development.Current neuropharmacology · 2025Review
- Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.International journal of molecular sciences · 2024Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid system, characterize the pro- and anticonvulsive effects of cannabinoids [e.g., Δ9-tetrahydrocannabinol and cannabidiol (CBD)], and highlight scientific evidence from pre-clinical and clinical trials of cannabinoids in epilepsy. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures. Finally, we discuss results from a new multicenter, open-label study using CBD in a population with treatment-resistant epilepsy. In all, we seek to evaluate our current understanding of cannabinoids in epilepsy and guide future basic science and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.